Alzheimer’ s Disease Diagnostic Market 2016: Market Segments, Landscape, Company Profiles, Demand and Forecast – 2022
Market Highlights
Alzheimer’ s is a type of dementia which causes failure of the functioning of the brain. This disease damages the areas which is responsible for the thinking, problem solving and behavior process. According to the Alzheimer’ s association, more than 5 million are living with Alzheimer’ s and one out of three seniors dies with the Alzheimer’ s or any another type of dementia.
One of the most common early symptoms of Alzheimer ' s is difficulty remembering newly learned information. As the Alzheimer ' s advances through the brain it leads to increasingly severe symptoms which include bafflement, mood and behavior swings, deepening confusion about events, time and place; unfounded thoughts about family, friends and professional caregivers and more serious memory loss and behavior changes; and difficulty speaking, swallowing and walking.
There are different types of tests to diagnose the symptoms of the Alzheimer’ s which includes Mini Mental State Exam( MMSE) this tests will help to know whether there are problems with the areas of brain involved in learning, memory, thinking, or planning skills. Other one is brain imaging which includes CT scan, Magnetic Resonance Imaging( MRI); Neuropsychological Testing and genetic tests which provide information regarding the incorrect linking of the genes which causes Alzheimer’ s among others.
Request a Sample Report @ https:// www. marketresearchfuture. com / sample _ request / 2149 Key Players:
� Eli Lilly and Company( UK), � TauRx( Republic of Singapore), � Alector LLC( US), � Accera, Inc.( US),
Tel: + 1-646-845-9349 sales @ marketresearchfuture. com